BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to natural killer (NK) cells. The invention also inc...

Full description

Saved in:
Bibliographic Details
Main Authors BRANDISH, Phil, DUFORT, Fay, UHLENBROICH, Sandra, MCDONNELL, Kevin, REPASH, Liz, KEEN, Nicholas, GAYNOR, Katie, CHEN, Liuhong, MUDD, Gemma, LEITHEISER, Chris
Format Patent
LanguageEnglish
French
Published 14.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to natural killer (NK) cells. The invention also includes multimeric binding complexes comprising at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands or said multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by natural killer (NK) cells, such as inflammatory disorders, autoimmune disease and cancer. La présente invention concerne des polypeptides qui sont liés de manière covalente à des échafaudages moléculaires de telle sorte que deux boucles peptidiques ou plus sont sous-tendues entre les points de fixation à l'échafaudage. En particulier, l'invention concerne des peptides qui se lient à des cellules tueuses naturelles (NK). L'invention concerne également des complexes de liaison multimère comprenant au moins deux desdits ligands peptidiques bicycliques. L'invention concerne également des compositions pharmaceutiques comprenant lesdits ligands peptidiques ou lesdits complexes de liaison multimère et l'utilisation desdits ligands peptidiques, des complexes de liaison multimère et des compositions pharmaceutiques dans la prévention, la suppression ou le traitement d'une maladie ou d'un trouble médié par des cellules tueuses naturelles (NK), telles que des troubles inflammatoires, une maladie auto-immune et un cancer.
Bibliography:Application Number: WO2022GB50043